Long-Term Follow-Up (LTFU) of Subjects Treated With NTLA 2002
Launched by INTELLIA THERAPEUTICS · Feb 7, 2024
Trial Information
Current as of July 25, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. A subject has completed or discontinued from an Intellia-sponsored or -supported treatment protocol in which a complete or partial dose of NTLA-2002 was received.
- • 2. A subject has provided informed consent for the LTFU study.
- • 3. A subject is willing to attend study visits, complete protocol-required follow-up schedule, and comply with the study requirements.
- Exclusion Criteria:
- • None
About Intellia Therapeutics
Intellia Therapeutics is a leading biotechnology company focused on the development of transformative therapies using CRISPR-based gene editing technology. Founded in 2014, Intellia is dedicated to advancing innovative treatments for genetic diseases, with a robust pipeline that includes both in vivo and ex vivo therapeutic approaches. The company's commitment to scientific excellence and collaboration has positioned it at the forefront of the biotechnology industry, driving progress in precision medicine and offering the potential for curative solutions to patients with unmet medical needs. Through rigorous clinical trials and a strong emphasis on safety and efficacy, Intellia aims to redefine the landscape of genetic healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lille, , France
Auckland, , New Zealand
Grenoble, , France
Cambridge, , United Kingdom
Amsterdam, , Netherlands
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported